

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Ertugliflozin / Metformin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Innishannon  
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4

H302: Harmful if swallowed.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

Precautionary statements : **Prevention:**

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.

### Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.

### Hazardous components which must be listed on the label:

metformin hydrochloride

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
metformin hydrochloride	1115-70-4 214-230-6	Acute Tox. 4; H302	>= 70 - < 90
Ertugliflozin	1210344-83-4	Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 STOT RE 2; H373 (Kidney, Stomach, Prostate)	>= 0.1 - < 1

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	595329-00019	Date of first issue: 01.04.2016

---

vice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	595329-00019	Date of first issue: 01.04.2016

---

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	595329-00019	Date of first issue: 01.04.2016

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | Use only with adequate ventilation.   |
| Advice on safe handling | : | Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Avoid prolonged or repeated contact with skin.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  |

#### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |   |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents                           |

#### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

- |                    |  |
|--------------------|--|
| dusts non-specific | 4 mg/m <sup>3</sup>  |
|                    | Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable) |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

dust)  
Basis: IE OEL

10 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)  
Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
metformin hydrochloride	1115-70-4	TWA	1 mg/m <sup>3</sup> (OEB 1)	Internal
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m <sup>3</sup>	IE OEL
Magnesium stearate	557-04-0	OELV - 8 hrs (TWA)	10 mg/m <sup>3</sup>	IE OEL
Ertugliflozin	1210344-83-4	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

#### Personal protective equipment

- Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to I.S. EN 143

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

Filter type : Particulates type (P)

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

Relative density : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	595329-00019	Date of first issue: 01.04.2016

---

Density : No data available

Relative vapour density : Not applicable

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Harmful if swallowed.

#### Product:



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

Acute oral toxicity : Acute toxicity estimate: 1,337 mg/kg  
Method: Calculation method

### Components:

#### **metformin hydrochloride:**

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg  
LD50 (Mouse): 1,450 - 3,500 mg/kg  
LD50 (Monkey): 463 mg/kg  
LD50 (Rabbit): 350 mg/kg  
LD50 (Guinea pig): 500 mg/kg

#### **Ertugliflozin:**

Acute oral toxicity : LD50 (Rat): 500 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available

### **Skin corrosion/irritation**

Not classified based on available information.

### Components:

#### **metformin hydrochloride:**

Species : Rabbit  
Result : Mild skin irritation

#### **Ertugliflozin:**

Result : Corrosive

### **Serious eye damage/eye irritation**

Not classified based on available information.

### Components:

#### **metformin hydrochloride:**

Species : Rabbit  
Result : Mild eye irritation

#### **Ertugliflozin:**

Result : Severe irritation

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Ertugliflozin:

Test Type : Local lymph node assay (LLNA)  
Result : Not a skin sensitizer.

#### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### metformin hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro assay  
Test system: mouse lymphoma cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

##### Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Rat  
Result: negative

#### Carcinogenicity

Not classified based on available information.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

### Components:

#### **metformin hydrochloride:**

Species : Mouse  
Exposure time : 91 weeks  
Dose : 1500 mg/kg body weight  
Result : negative

Species : Rat, male  
Application Route : Oral  
Exposure time : 104 weeks  
Dose : 900 mg/kg body weight  
Result : negative

Species : Rat, female  
Application Route : Oral  
Exposure time : 104 weeks  
LOAEL : 900 mg/kg body weight  
Result : negative  
Target Organs : Uterus (including cervix)  
Remarks : The mechanism or mode of action may not be relevant in humans.

#### **Ertugliflozin:**

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

#### **Reproductive toxicity**

Not classified based on available information.

### Components:

#### **metformin hydrochloride:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 600 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

Developmental Toxicity: NOAEL: 600 mg/kg body weight  
Result: No teratogenic effects

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 140 mg/kg body weight  
Result: No teratogenic effects

### Ertugliflozin:

Effects on fertility

: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 250 mg/kg body weight  
Remarks: Maternal toxicity observed.  
No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 200 mg/kg body weight  
Remarks: No significant adverse effects were reported

Effects on foetal development

: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 250 mg/kg body weight  
Remarks: No significant adverse effects were reported

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Components:

#### Ertugliflozin:

Exposure routes : Oral  
Target Organs : Kidney, Stomach, Prostate  
Assessment : May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

### Repeated dose toxicity

#### Components:

##### **metformin hydrochloride:**

Species : Rat  
NOAEL : 125 mg/kg  
Application Route : Oral  
Exposure time : 1 year  
Remarks : No significant adverse effects were reported

Species : Rabbit  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 1 Year  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 50 mg/kg  
Application Route : Subcutaneous  
Exposure time : 2 year  
Remarks : No significant adverse effects were reported

##### **Ertugliflozin:**

Species : Rat  
LOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 30 d

Species : Rat  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Kidney

Species : Rat  
LOAEL : 25 mg/kg  
Application Route : Oral  
Exposure time : 180 d  
Target Organs : Kidney, Bone, Stomach

Species : Rat  
LOAEL : 25 mg/kg  
Exposure time : 90 d  
Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog  
NOAEL : 150 mg/kg  
Application Route : Oral  
Exposure time : 270 d  
Remarks : No significant adverse effects were reported

Species : Mouse

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 28 d  
Target Organs : Bone  
Remarks : No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### metformin hydrochloride:

Skin contact : Remarks: May irritate skin.  
Eye contact : Remarks: May irritate eyes.  
Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Gastrointestinal discomfort, flatulence, asthenia, Fatigue, Headache

##### Ertugliflozin:

Ingestion : Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### metformin hydrochloride:

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

- NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- Toxicity to fish (Chronic toxicity) : NOEC: 10 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 40 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211
- Ertugliflozin:**
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- NOEC : 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- Toxicity to fish (Chronic toxicity) : NOEC: 1 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 2.14 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

### 12.2 Persistence and degradability

#### Components:

##### **metformin hydrochloride:**

Biodegradability : Result: rapidly degradable  
Biodegradation: 50 %  
Exposure time: 2 hrs

##### **Ertugliflozin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 40.8 %  
Exposure time: 28 d

### 12.3 Bioaccumulative potential

#### Components:

##### **metformin hydrochloride:**

Partition coefficient: n-octanol/water : log Pow: -2

##### **Ertugliflozin:**

Partition coefficient: n-octanol/water : log Pow: 2.47

### 12.4 Mobility in soil

#### Components:

##### **metformin hydrochloride:**

Distribution among environmental compartments : log Koc: 4.3  
Method: OECD Test Guideline 106

##### **Ertugliflozin:**

Distribution among environmental compartments : log Koc: 2.88

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

---

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

- Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
- 

## SECTION 14: Transport information

### 14.1 UN number or ID number

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.4 Packing group

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	595329-00019	Date of first issue: 01.04.2016

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA (Cargo)** : Not regulated as a dangerous good  
**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.  
Not applicable

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 595329-00019      Date of last issue: 04.04.2023  
Date of first issue: 01.04.2016

### SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of H-Statements

H302 : Harmful if swallowed.  
H314 : Causes severe skin burns and eye damage.  
H318 : Causes serious eye damage.  
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Eye Dam. : Serious eye damage  
Skin Corr. : Skin corrosion  
STOT RE : Specific target organ toxicity - repeated exposure  
IE OEL : List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2  
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	595329-00019	Date of first issue: 01.04.2016

---

- Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Acute Tox. 4

H302

### Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN